Results of Hematology/Oncology Pharmacy Association and Eisai Inc. Survey Show 83 Percent of Patients Receiving Chemotherapy May Be Unnecessarily Suffering from Chemotherapy-induced Nausea and Vomiting
Findings suggest need for improved dialogue between patients receiving chemotherapy and their healthcare team, including pharmacists

WOODCLIFF LAKE, N.J., Oct. 19, 2015 /PRNewswire/ -- Results from two national surveys of patients receiving chemotherapy and pharmacists, conducted by the Hematology/Oncology Pharmacy Association (HOPA) in collaboration with Eisai Inc.,* found that 83% of patients receiving chemotherapy who have experienced chemotherapy-induced nausea and vomiting (CINV) believe it is a side effect with which they must live. Results also showed that 95% of cancer patients surveyed believe that CINV has, at some point, had an impact on their daily lives. These national surveys are part of the Time to Talk CINV™ campaign, which aims to increase awareness among patients and caregivers about CINV prevention and the importance of speaking with their pharmacist and full healthcare team about this often preventable side effect.

Experience the interactive Multimedia News Release here 

"The survey results underscore the confusion patients who are undergoing chemotherapy have about CINV and the need for them to understand that there are ways to manage their symptoms so that they do not have to needlessly suffer with CINV," said Scott Soefje, PharmD, MBA, BCOP, President, Hematology/Oncology Pharmacy Association (HOPA) and Director of Pharmacy at the University Medical Center Brackenridge in Austin, TX. "It is imperative that patients discuss CINV prevention early in treatment and with all members of the health care team, including pharmacists."

The patient survey, conducted by Wakefield Research on behalf of HOPA and Eisai Inc., involved 400 patients age 18 and over receiving chemotherapy and the pharmacist survey, conducted by HOPA, involved 200 HOPA members. Other key survey findings are highlighted below. 

Lack of CINV understanding is widespread:

  • Nearly one-third of respondents thought that experiencing CINV was a sign that chemotherapy was working
  • Approximately 4 in 5 respondents who have experienced CINV agreed that their CINV was under control if they were not vomiting

CINV has a significant impact on patients' daily lives:

  • Nearly 3 in 4 patients who have experienced CINV said CINV made them want to avoid future cancer treatments and the vast majority said CINV caused them to alter their lives at some point in ways including:
    • More than half of patients (56%) cancelled personal plans
    • Nearly half of patients (46%) changed their eating habits
    • 43% avoided exercise or physical activity
    • 38% called in sick to work

"When I first started receiving chemotherapy, I didn't realize that the nausea and vomiting I was experiencing 4 to 5 days later, and sometimes during important family events, was something that could be prevented or controlled," said Mary Van Dyke, an ovarian cancer survivor. "Once I spoke up to my pharmacist about my CINV, we were able to adjust my plan to better prevent it and get me back to enjoying time with my family."

Pharmacists are looking for ways to improve and increase communication about CINV:

  • Nearly 85% of pharmacists said additional materials would help with their communication about CINV with their patients.

"At Eisai, we understand the important role that pharmacists play with patients to advance the goal of preventing CINV," said Sheryl Lapidus, director, Corporate Advocacy at Eisai, Inc. "As a company dedicated to fulfilling the unmet medical needs of cancer patients and their families, we look forward to working with HOPA to use these survey results as a guide to provide new resources that may help educate patients and their caregivers about CINV prevention."

In response to these findings, HOPA, in collaboration with Eisai, is launching the Time to Talk CINVcampaign to encourage patients going through chemotherapy to talk openly with their pharmacist and full healthcare team in order to understand more about CINV and how it may be prevented. The campaign will include tools designed to help encourage and improve conversations about CINV between pharmacists and patients. The tools will be available early next year.

For more information, visit and

About CINV 
CINV is one of the most distressing side effects of chemotherapy for the up to 1.8 million cancer patients in the United States who receive chemotherapy as part of their cancer treatment each year. Approximately 70-80% of patients who do not receive appropriate preventive care will experience at least some level of CINV. Two types of CINV include acute CINV, which occurs within 24 hours after a patient receives chemotherapy, and delayed CINV, which occurs more than 24 hours after chemotherapy administration. Delayed CINV is often the least well-managed type of nausea and vomiting.

About the Surveys 
The patient survey was conducted by Wakefield Research, on behalf of HOPA and Eisai Inc., between July 9 and July 24, 2015, using an email invitation and an online survey among 400 patients receiving chemotherapy, age 18 and over. Among the respondents, 47% were female and 53% were male, with 36.5% under the age of 40 and 63.5% age 40 or older. Respondents were from the South (35%), West (26%), Midwest (17%) and Northeast (22%).

The pharmacist survey was conducted by HOPA among 200 members of the Association between July 8 and July 28, 2015 using an email invitation and online survey.

About HOPA
HOPA is a nonprofit professional organization formed in 2004 to help oncology and hematology pharmacy practitioners and their associates provide the best possible cancer care. HOPA supports research, conducts educational conferences to advance knowledge, encourages professional development and advocates for health policy issues that improve patient care. HOPA has more than 2300 members and includes oncology pharmacists, as well as pharmacy interns, residents, nurses, technicians, researchers, and administrators specializing in hematology/oncology practice. To learn more about HOPA, visit

About Eisai Inc.
At Eisai Inc., human health care is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of commercial focus include oncology and specialty care (Alzheimer's disease, epilepsy and metabolic disorders). To learn more about Eisai Inc., please visit us at​.

Eisai Inc. has affiliates that are part of a global product creation organization that includes R&D facilities in Massachusetts, New Jersey and Pennsylvania, as well as a global demand chain organization that includes facilities in Maryland and North Carolina. Eisai's global areas of R&D focus include neuroscience; oncology; metabolic disorders; vascular, inflammatory and immunological reaction; and antibody-based programs.

*The Time to Talk CINV™ campaign is funded by Eisai Inc.


Media Inquiries (Eisai)

Media Inquiries (HOPA)

Investor Inquiries (Eisai)

Teresa Cronin

Elizabeth Sherman

Alex Scott

Eisai Inc.


Eisai Inc.

(201) 949-4326

(847) 375-6307

(201) 746-2177



To view the original version on PR Newswire, visit:


SOURCE Eisai Inc.

Type Press Release

Date Released October 19, 2015

Jun 1, 2020

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the availability of DAYVIGO™ (lemborexant) CIV for the treatment of adults with insomnia, characterized by...

May 29, 2020

Eisai today announced updated results from ENHANCE 1, a Phase 1b/2 study exploring the investigational combination of eribulin plus pembrolizumab in patients with metastatic triple-negative breast...

May 28, 2020

KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., May 28, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced new data from analyses of two trials...

Alerts - Release page
* Required Fields